Thromb Haemost 1972; 28(02): 228-236
DOI: 10.1055/s-0038-1649059
Original Article
Schattauer GmbH

Effect of Lidoflazine (R 7904) on Human Platelet Function in Vitro

F De Clerck
1   Cardiovascular Research Department Janssen Pharmaceutica Research Laboratories, Beerse, Belgium
› Author Affiliations
Further Information

Publication History

Publication Date:
24 July 2018 (online)

Preview

Summary

The effect of lidoflazine and of cinnarizine on human platelet function in vitro was compared to that of dipyridamole.

Pre-incubation for 30 min at 37° C of platelet rich plasma with lidoflazine or with dipyridamole 5 ×10–4 M resulted in an appreciable inhibition of collagen aggregation in particular and to a lesser extent of ADP aggregation; cinnarizine was marginally active only.

Clot retraction was inhibited by lidoflazine and by dipyridamole. Experiments on biphasic ADP aggregation and C14-serotonin release during aggregation show that lidoflazine reduces the platelet release reaction.

The possible mode of action of the compound is discussed.

Plasma coagulation and PF – 3 availability were not affected.